Figure 3.

Primary AML blasts cultured ex vivo were treated with increasing concentrations of emvododstat or its inactive enantiomer PTC-371 at 37°C for 72 hours. Samples were then stained with appropriate antibodies and evaluated using a flow cytometer. For panels (A-D), values represent the mean ± SD for triplicate values. Decrease in the fraction relative to control of (A) total blast cells treated with emvodostat, (B) total blast cells treated with PTC-371, (C) immature blast cells treated with emvodostat, or (D) lymphocytes treated with emvodostat. (E) Flow cytometry analysis of primary AML patient samples. Shown are data from blood obtained from 5 AML subjects incubated ex vivo with 100 nM emvodostat or DMSO.